UK's CMA Goes After Advanz, Morningside And Alliance On Nitrofurantoin
Executive Summary
The UK’s Competition and Markets Authority has issued a statement of objections to Advanz, Morningside and wholesaler Alliance Healthcare after provisionally finding that the firms broke competition law by arranging to carve up the UK market for nitrofurantoin.
You may also be interested in...
UK-Based Morningside Snapped Up By US Private Equity
Aspire Pharma’s takeover of Morningside and its related subsidiaries will create “the UK’s premier Specialty Pharma company,” becoming one of “the largest and fastest growing UK pharma companies.”
UK’s CMA Issues £35m In Fines Over Prochlorperazine
Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.
UK’s CMA Issues £35m In Fines Over Prochlorperazine
Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.